Investigational Clinical Amyloid Research in Alzheimer's
ID Number 08-0241-00002Principal Investigator(s)
Hillel T. Grossman
Department(s) or Division(s)
The purpose of this study is to demonstrate an advantage of the efficacy of multiple doses of intravenously (IV) administered bapineuzumab in subjects with mild to moderate AD (Alzheimer's Disease) over placebo on cognitive and global measures. This placebo controlled study will evaluate the effect and safety of multiple doses of intravenously administered bapineuzumab in subjects and subject populations with mild to moderate AD.
Recruiting Patients: No